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ABSTRACT 
Objective: This study aim to investigate the levels of oxidative stress, antioxidants besides uric acid, C-reactive protein (CRP), lipid profile and 
cardiac biomarker enzymes in young men admitted to the hospital for the first time with acute myocardial infarction (AMI), to investigate any 
Relationship between them. 
Methods: 135 young men age ˂ 40 y old, admitted to the cardiology unit with suspected MI and 130 age and sex matched healthy controls were 
included in this study. Blood samples were collected from the patients and the control group. The blood samples were collected from the patients on 
the day of admission and on the day of discharge. 
Results: The levels of xanthine oxidase (XO), malondialdehyde (MDA), CRP, uric acid, total cholesterol (TC), total triglyceride (TG), low-density 
lipoprotein (LDL-C), apoprotein-B 100 (Apo B), and cardiac biomarker enzymes were significantly high, whereas catalase, vitamin C, high-density 
lipoprotein (HDL-C) and apoprotein-A1 (Apo A1) were significantly low on the day of admission (Time A) and slightly higher on the day of discharge 
(Time B), but both were still lower than the controls. There was a decrease in XO and MDA activity and an increase in catalase activity and vitamin C 
level. 
Conclusion: These results may indicate possible relationships between these parameters and AMI. 
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INTRODUCTION 
Cardiovascular diseases, particularly acute myocardial infarction 
(AMI), are the most alarming health predictors of the new 
millennium and are considered to be the leading cause of death 
worldwide [1-3]. Nearly half of these deaths are more likely to occur 
in young and middle-aged individuals [2]. In the younger age 
population, the rate of AMI is 5% [3]. AMI is commonly known as 
“heart attack” results from ischemic necrosis of a variable amount of 
myocardial tissue as a result of an abrupt acute decrease in coronary 
flow or increase in myocardial demand for oxygen, which cannot be 
supplied by obstructed coronary artery [4-6]. 
The assessment of the myocardial injury varys dramatically with the 
detection of aspartate aminotransferase (AST), lactate dehydro-
genase (LDH), creatine kinase (CK), creatine kinase isoenzymes (CK-
MB), and troponin (T) which add prognostic information regarding 
acute short-term or chronic long–term risk and the severity of the 
injury [6-7].  
Growing evidence support the involvement of oxidative stress due to 
an imbalance between the production of reactive oxygen species 
ROS (including the superoxide anion, hydrogen peroxide, and 
hydroxyl radical) and endogenous antioxidant defense mechanism 
[1] which plays an important role in the pathogenesis and 
progression of heart failure [8-10]. The imbalance can exert 
profoundly deleterious effects on endothelial function and 
monocytes migration [8]. An oxygen free radical generation has 
been shown to be an important mechanism of cellular injury in the 
ischemic myocardium [11]. Several mechanisms have been 
proposed to be involved in the generation of oxygen free radicals, 
but xanthine oxidase has been shown to be a major source of free 
radical generation under ischemic conditions [12-13]. Xanthine 
oxidase (XO) is an enzyme that catalyzes the chain reactions of 
hypoxanthine oxidizing to xanthine and xanthine oxidizing to uric 
acid and hydrogen peroxide [14]. Under ischemic conditions, XO is 
produced. It acts on both hypoxanthine and xanthine at the expense 
of molecular oxygen producing superoxide ion [15]. Therefore, in 
ischemic conditions of the heart such as MI, XO plays a pathologic 
role in heart failure [16]. 
Uric acid production is elevated in association with increased 
xanthine oxidase activity. Elevated levels of uric acid correlate with 
impaired hemodynamics [17] and independently predict an adverse 
prognosis in heart failure [17] and therefore elevated serum uric 
acid may act as a marker of underlying tissue ischemia [18]. 
CRP is an emerging risk marker that is recommended to 
complement the assessment of patients at primary cardiovascular 
risk and to a more limited extent, stable patients at secondary risk. 
Several trials have demonstrated the strong predictive value of CRP 
in stable and unstable angina, independent of troponin and burden 
of atherosclerosis [19-20]. 
Oxidative stress and inflammation are two processes that appear to 
have a significant role in the risk of AMI [21-22]. Increased levels of 
low-density lipoprotein cholesterol (LDL-C) are known as one of the 
major risk factors in atherosclerotic disease [23]. Epidemiological 
studies have shown that apolipoprotein B-100 (Apo B), with or 
without Apo A1, is a better predictor of coronary artery disease than 
LDL-C and other non-HDL lipoproteins [24-25]. One of the most 
frequently used biomarkers indicating lipid peroxidation is plasma 
concentration of malondialdehyde (MDA). This molecule is one of 
the end products of lipid peroxidation in the cell membrane or in 
LDL-C [26-27].  
Antioxidants are either endogenous or exogenous compound that 
prevent the generation of harmful free radicals, reduce the 
generated radicals, inactivate their harmful reactivity, and thereby 
block the chain reactions of these oxidants [27].  
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Myocardial antioxidants inhibit or delay the oxidative damage to 
subcellular proteins, carbohydrates, lipids and DNA. This is achieved 
mainly by the activities of enzymatic antioxidants such as catalase or 
non-enzymatic antioxidants such as vitamin C; these have been 
reported as predictive indices of CAD [28]. Catalase is believed to 
play a major role in the first line of enzymatic antioxidant defense. 
Catalase reacts efficiently in peroxisomes with hydrogen peroxide 
(H2O2) to form water and molecular oxygen [29-30]. It was observed 
that antioxidant vitamin C abolished the malondialdehyde-induced 
negative contractile response which suggests that MDA may elicit its 
inhibitory effect associated with enhanced oxidative stress in the 
heart. Antioxidant vitamin C also had been shown to stimulate the 
immune system; shown to block damaged pathways through the 
stimulation or maintenance of T cell proliferation in response to 
infection [31]. 
The aim of this study is to assess the extent of oxidative stress such 
as xanthine oxidase (XO) and MDA levels, the levels of enzymatic 
antioxidants such as catalase and non-enzymatic antioxidants 
vitamin C, alongside the measurement of CRP, uric acid, lipid profile, 
and cardiac biomarkers enzymes in young Arabian AMI patients and 
compare them to healthy controls. 
MATERIALS AND METHODS 
135 male inpatients, aged 38.2±5.3 y with BMI<25 kg/m2 and AMI 
admitted to the hospital for the first time were investigated. The 
study included 130 age, sex, height, and body weight-matched group 
of healthy individuals were set as control. Clinical examinations of 
all patients were performed to detect any co-existing disorder to be 
excluded. All patients were organic disorders free, and none of them 
were smokers or on anti-hyperlipidemia, antioxidant or vitamin 
supplements medication. Consent for all procedures was obtained 
from the patients and the healthy controls. The study was approved 
by the hospital’s ethics committee and was in accordance with the 
ethical standards. Diagnosis of AMI was based on the clinical history, 
typical chest pain lasting 30 min or longer, electrocardiographic 
(ECG) signs of infarction and elevated serum enzymes, including CK, 
AST, LDH, isoenzymes MB (CK-MB) and troponin T within 12h after 
the onset of pain. Both patients and healthy controls were subjected 
to routine investigations. 
Preliminary evaluation  
10 ml of venous blood samples were collected from patients with AMI 
and from the controls by vein puncture. For this study, the blood 
samples of AMI patients were collected on the day of admission (Time A) 
and on the day of discharge from the hospital (after 5-7d, Time B).  
The blood samples were centrifuged at 3000 rpm for 10 min after 
allowing the blood to clot at room temperature. The serum was 
assayed immediately to detect the enzymatic markers of tissue 
damage. AST, LDH, CK, CK-MB were measured using the standard 
technique (Cobas 8000 Analyzer, Roch Diagnostics GmbH, 
Germany). Troponin T was analyzed using commercially available 
sandwich ELISA kit (Roch Diagnostics, Germany) and performed as 
described by the manufacturer. Results were expressed as unit/l 
(IU/l) of enzyme activity evaluated in serum. CRP levels were 
determined by a Nephelometric method using Beckman Array 
protein system, USA. 
Biochemical parameters detection  
Biochemical parameters were detected in the sera of the patients 
and the controls. TC was measured by an Enzymatic (CHOD-PAP) 
colorimetric method [32], TTG was measured by an Enzymatic 
(GPO-PAP) method [33], HDL-C was estimated by a Precipitant 
method [34], and LDL-C was estimated using Friedewalds formula 
[35] as has been shown: LDL-C= TC–HDL-C–(TG/5), glucose [36], 
uric acid [37]. Serum Apo A1 and Apo B were measured by Immuno 
nephelometry (Dade Behring, Marburg, Germany). 
The estimation of serum lipid peroxidation (MDA), XO and 
antioxidant (vitamin C and catalase) 
Lipid peroxidation product (MDA) was estimated by measurement 
of thiobarbituric acid reactive substances in plasma by the method 
of Buege and Aust [38]. The pink chromogen produced by the 
reaction of the thiobarbituric acid with malondialdehyde, a 
secondary product of lipid peroxidation was estimated. The 
absorbance of the clear supernatant was measured against reference 
blank at 535 nm.  
XO catalyzes the oxidation of hypoxanthine to xanthine and then 
catalyzes the oxidation of xanthine to uric acid. It was estimated by 
the method of Nishino [39]. The rate of formation of uric acid is 
determined by measuring increased absorbance at 290 nm. A unit of 
activity is that forming one µmol of uric acid/min. 
Vitamin C was estimated by the method of Roe and Kuether [40] on 
the basis of the oxidation of ascorbic acid by copper followed by 
treatment with 2,4-dinitrophenylhydrazine that undergoes 
rearrangement to form a product with an absorption maximum at 
520 nm. 
Catalase activity was measured according to the Spectrophotometric 
method of Goth [41]. This assay is based on the ability of hydrogen 
peroxide to form a stable stained complex with ammonium 
molybdate measured at 405 nm. 
Statistical analysis  
Statistical analysis was carried out using Student's t-test by 
statistical packages for social science software (SPSS). Values are 
expressed as mean±SD and values of p<0.05 were considered 
statistically significant. The relationships between variables were 
calculated using Pearson Correlation Coefficients.  
RESULTS 
The levels of the cardiac biomarkers in the serum of young AMI 
patients and in the controls are shown in table 1. 
  
Table 1: Serum levels of cardiac markers in young male AMI patients and in the controls 
Parameter Controls n=130 Patients n=135 
Admission day (time A) Discharge day (time B) 
AST (IU/l) 23.2±3.3  39.61±9.1* 24.11±12.6† 
 LDH (IU/l)  185.3±32.7 268.4±39.6*  180.21±34.9† 
 CK (IU/l)  68.2±18.7 131.2±21.6*  70.4±20.1† 
CK-MB (IU/l) 13.21±4.7 88.62±13.4* 14.32±2.34† 
Troponin T (ng/ml) 0.031±0.01 1.16±0.27* 0.061±0.007† 
Values represent the means±standard deviation, AST, aspartate transaminase; LDH, lactate dehydrogenase; CK, creatine Kinase;  
CK-MB, isoenzyme, T, troponin. 
*P<0.0001 significant differences between AMI patients (Time A & B) and control subjects. 
†P<0.0001 significant differences between AMI patients in (time A) and (time B). 
-No significant differences were seen between the AMI patients in (time B) and control subjects. 
There were significant increases in the serum levels of AST, LDH, 
CK, and CK-MB, and troponin T between AMI patients (time A) 
when compared with AMI patients at (time B) and the control 
subjects. There was no difference in the serum levels of AST, LDH, 
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CK, and troponin T between AMI patients (time B) when compared 
to the control subjects. 
The changes in the biochemical parameters in the AMI patients are 
shown in table 2. 
 
Table 2: Comparison of biochemical changes in young male AMI patients and in the controls 
Parameters Controls n=130 AMI n=135 
Admission day (Time A) Discharge day (Time B) 
CRP (mg/dl)  0.51±0.081 5.88±1.01*  6.01±1.11*c 
Fasting glucose (mg/dl)  98.6.1±10.41  103.55±12.31 96.55±95+13.2 
Uric acid (mg/dl)  2.91±0.81 7.91±1.91*  5.33±1.61*bc 
Total cholesterol (mg/dl)  169.6±20.66  249.81±30.32* 218.31±18.96*ac 
Total triglyceride (mg/dl)  113.18±18.1  250.89±33.89* 181.25±26.31*ad 
LDL cholesterol (mg/dl) 104.11±13.91  165.71±22.81*  113.53±19.71†a 
HDL cholesterol (mg/dl)  56.63±12.31  39.44±9.21*  48.81±11.51†bc 
Apo A1 (mg/dl) 145.13±13.61  120.6±8.81*  128.91±7.21*c 
Apo B (mg/dl) 98.33±14.33  156.91±18.44*  125.91±31†bd 
CRP; C-reactive protein, LDL; low-density lipoprotein, HDL; high-density lipoprotein, Apo; apolipoproteins, Values represent the means±standard 
deviation,  
*P<0.0001, †P<0.001significantly different between AMI patients (time A & B) and the Controls. 
aP<0.001; bP<0.01significantly different between AMI patients on the day of admission (time A) and the day of discharge (time B) 
cP<0.0001; dP<0.001, significantly different between the day of discharge of patients and the controls. 
 
The comparison of biochemical parameters in the controls and in 
the AMI patients is shown in table 2, and indicate that the patients 
had a significant increase in the levels of CRP, uric acid, TC, TG, LDL-
C, Apo B levels but significant decrease in HDL-C and Apo A1 levels 
than the controls. 
On the other hand, when comparing the levels in the AMI patients on 
discharge time (time B) to the levels at the admission time (time A), 
the AMI patients in time A had significantly lower levels of uric acid, 
TC and LDL-C and apo B, but no change in apo A1 and significantly 
higher levels of HDL–C. 
 
Table 3: The levels of the circulating oxidants and antioxidants in young male AMI patients and in the controls 
Parameters Controls n=130 AMI n= 135 
Time A Time B 
XO units/mg protein  0.011±0.006  0.071±0.008* 0.056±0.005*bc 
Serum MDA (μmol/l) 0.98±0.071  1.64±0.60*  1.21±0.71*ac 
Serum catalase (µmol of H2O2 consumed/min/mg protein)  59.1±9.31  41.34±6.21†  49.53±8.41†bc 
Vitamin C (mg/dL)  1.31±0.23  0.54±0.31*  0.86±0.25*bc 
Values represent the means±standard deviation, XO; xanthine oxidase, MDA; malonaldehyde.  
*P<0.0001; †P<0.001 significantly different between AMI patients (time A & B) compared to the control subjects 
aP<0.001; bP<0.01 significantly different between AMI patients on the day of admission (time A) and the day of discharge (time B)  
cP<0.001; dP<0.01 significantly different between the day of discharge and controls. 
 
Table 3 shows circulating oxidants and antioxidants in young AMI 
patients and in the controls. As shown in table 3, serum xanthine 
oxidase and malondialdehyde (MDA) activity were significantly 
higher in AMI patients (in time A and slightly less in time B) but yet 
the levels were higher than in the controls.  
The activity of antioxidant catalase and vitamin C were significantly 
low in AMI patients at time A and slightly higher at time B but 
significantly lower than the controls. 
DISCUSSION 
Myocardial infarction or heart attack results from the interruption of 
blood supply to a part of the heart, causing heart cells to die after 
about 30 min of anoxia. As a result of cell death, the acute 
inflammatory response cause leukocytosis, increased levels of acute 
phase reactant proteins in the circulation, particularly C-reactive 
protein [14, 42], elevated markers of inflammation as CRP which are 
associated with increased risk of further cardiovascular disease as 
AMI [19], and CRP appears to provide predictive value for short-
term prognosis in AMI [18]. In this study, serum CRP levels in AMI 
patients are significantly higher when compared to the control 
subjects on the day of admission and at the day of discharge. In 
addition, due to the increase in the levels of CRP, liberation of 
intracellular contents and their appearance in the circulation was 
detected, particularly enzymes measured for the purpose of 
diagnosing AMI including CK, CK-MB, AST, LDH and troponin T. 
Elevated levels of these enzymes, especially CK-MB, have been 
regarded as biochemical markers of myocyte necrosis, and still have 
a place in defining AMI [43]. In this study, increase CK-MB levels 
were found in patients with AMI as compared to the controls. The 
peak is usually on the day of admission and returns to baseline level 
at the day of discharge. As expected in this study, the changes in each 
of the serum enzyme activities after AMI, measured on the day of 
admission and on the day of discharge, exhibit a specific time course 
as shown in table I. Our results are in accordance with other reports 
[6, 42, 44, 45]. The troponins are highly sensitive and specific 
markers of myocardial damage [43]. In accordance with this, our 
results indicate high levels of serum troponin in patients with AMI in 
the day of admission followed by a decline not reaching the baseline 
at the day of discharge in comparison to the controls.  
Several studies have identified the importance of serum uric acid 
concentration in young populations in predicting the risk of 
cardiovascular disease, such as AMI [46]. This study shows that 
serum uric acid levels are higher in younger patients with AMI on 
the day of admission and the day of discharge when compared to the 
control. Serum uric acid has antioxidant properties and contributes 
to free radical scavenging activity in human serum [47], thus, uric 
acid can be protective against oxidative stresses, but it can also lead 
directly or indirectly to vascular injury [47]. High levels of serum 
uric acid may induce endothelial dysfunction by decreasing the 
production of nitric oxide, which is a potent vasodilator in the 
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vascular endothelial cells [47]. In this study, there is a significant 
increase in serum uric acid concentration. Our results agree with 
most of the other studies that suggest that elevated serum uric acid 
may act as a marker for tissue ischemia, cardiac failure and 
myocardial infarction [18, 19]. 
In AMI, dyslipidemia has been reported to be the most threatening 
risk. Most of the previous lipid profile studies in AMI patients found 
higher TC, TG, LDL-C apo B and lower HDL-C and apo A1 [48-49], 
which agrees with our finding in young AMI patients. Numerous 
researchers have confirmed the association between a low HDL and 
increased risk of coronary heart disease. The levels of LDL correlates 
positively, whereas the levels of HDL correlates negatively [50]. This 
is in accordance with our results. HDL is considered the most 
important protective factor against arteriosclerosis due to its active 
participation in the reverse transport of cholesterol [51]. Increased 
oxidative stress and the generation of free oxygen radicals result in 
the modification of LDL to oxidized LDL that could lead to 
atherosclerotic lesions [51-52].  
Oxygen free radicals which are responsible for elevated actions of 
oxidative stress has been considered as one of the most important 
mechanism of cellular injury and progression of atherosclerosis in 
ischemic myocardial infarction [11]. Oxidative stress is associated 
with increased formation of reactive oxygen species (ROS) that 
modifies phospholipids and proteins leading to peroxidation and 
oxidation of thiol group [53]. It is also associated with abnormalities 
in myocyte function [53-54]. These effects correlate with an increase 
in MDA in sarcolemma [53]. Increased oxidative stress is recognized 
to be important in the pathogenesis of cardiovascular diseases [18, 
54]. The study of the interaction of free radicals with lipids can be 
readily carried out to assess the free radical-mediated damage. 
Lipids, when reacted with free radicals, undergo peroxidation to 
form lipid peroxides. Lipid peroxides decompose to form numerous 
products including malondialdehyde. Our data show that MDA 
increased significantly in AMI on the day of admission when 
compared to the levels on the day of discharge. The decrease in 
levels did not reach the control levels. The increase in the levels of 
MDA in the serum of patients with AMI indicate an increase in lipid 
peroxidation and is one of the significant markers that indicate 
oxidative stress associated with AMI and also agrees with previous 
studies [48, 55]. The changes in the levels of plasma lipids as shown in 
our study are complications frequently observed in AMI patients [50].  
XO catalysis of the reaction that generates oxygen free radicals is 
considered one of the most significant. The enzyme acts in the 
metabolism of purine, converting both hypoxanthine and xanthine to 
uric acid at the expense of molecular oxygen to produce superoxide 
ions, which oxidize cellular proteins and membranes resulting in 
myocardial cellular injury [52, 56]. In the present study, the finding of 
high levels of XO activity in the blood of patients with AMI compared 
to the levels in the control subjects indicate that myocardial ischemia 
has a definite correlation with XO activity, suggesting that XO is 
specifically involved in the mechanism of peripheral endothelial 
dysfunction, and it could play a crucial role in the generation of ROS in 
the body [16]. XO can be used as a biochemical indicator of AMI, along 
with Electrocardiography observations [56]. Under normal 
physiological conditions, ROS production is balanced by an efficient 
system of antioxidants which are molecules that are capable of 
scavenging ROS and thereby preventing oxidant damage. At the 
cellular level, these are naturally occurring enzymatic antioxidants 
such as catalase and non-enzymatic antioxidant such as water 
soluble antioxidant vitamin C. In this study catalase and vitamin C 
levels were significantly lower in AMI patients than in the control 
subjects, suggesting that AMI is able to increase oxidative stress to 
the point of severe damage to the antioxidant system, which is 
unable to prevent oxidative stress and inflammation [57]. 
CONCLUSION 
This study shows a significant increase in lipid peroxidation, in total 
oxidant status and a significant decrease in antioxidant status in 
young male patients with AMI. This indicates an imbalance between 
oxidant and antioxidant molecules requiring rectification as this can 
cause other comorbidities. The association between oxidant stress 
parameters, antioxidant markers, the inflammatory index and the 
lipid status parameters suggest their involvement in AMI 
development.  
We conclude that apart from the enzymatic markers of tissue 
damage and lipid profile, other factors may increase the risk of 
further myocardial events. An example is inflammatory markers like 
CRP which may need to be monitored at regular intervals. Futhure 
prospective studies in larger data include different populations are 
needed to confirm our data. Nevertheless, this finding should be 
supported by research that is more extensive in order to put it into 
practice.  
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